Vivo Capital

Vivo is a global healthcare investment platform that has dedicated strategies spanning from venture capital, private equity and public equity. We seek to foster innovation and growth in the global healthcare market via our unique Ecosystem Approach

Dr. Kung is a founding member and partner of Vivo Capital. Dr. Kung started his career in the biotech industry in 1979 when he joined Cetus Corporation. He co-founded Cetus Immune Corporation in 1981, which was acquired by its parent company Cetus in 1983. In the same year he co-founded Genelabs Technologies, Inc. where he served as the Chairman and CEO until 1995. During his tenure at Genelabs, he brought the company public in 1991 (NASDAQ: GNLB) and built it to a 175 employee international biotech company with operations in the United States, Belgium, Singapore, Switzerland, and Taiwan.

Dr. Kung received his B.S. in chemistry from the National Tsing Hua University in Taiwan and his Ph.D. in molecular biology and M.B.A. from the University of California, Berkeley. He received the Best Use of Technology Award from the Governor of California as well as Entrepreneur of the Year Awards from Ernst and Young and the Asian Business League. He also served on the board of directors for the Emerging Company Governing Body of the Biotechnology Industry Organization (BIO), Mt. Jade Science and Technology Association (West Coast), and the Asian American Manufacturing Association. He was appointed by the U.S. Secretary of Health and Human Services as a voting member of the National Biotechnology Policy Board.

Sinovac Biotech Ltd - June 11, 2025

Below is a list of company engagements where the filer has filed a Schedule 13D and/or engaged in a proxy campaign. As the filer does not file a Form 13F, current ownership information is not available.